Literature DB >> 25563444

A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.

S Turton, D J Nutt, R L Carhart-Harris1.   

Abstract

BACKGROUND: This report documents the phenomenology of the subjective experiences of 15 healthy psychedelic experienced volunteers who were involved in a functional magnetic resonance imaging (fMRI) study that was designed to image the brain effects of intravenous psilocybin.
METHODS: The participants underwent a semi-structured interview exploring the effects of psilocybin in the MRI scanner. These interviews were analysed by Interpretative Phenomenological Analysis. The resultant data is ordered in a detailed matrix, and presented in this paper.
RESULTS: Nine broad categories of phenomenology were identified in the phenomenological analysis of the experience; perceptual changes including visual, auditory and somatosensory distortions, cognitive changes, changes in mood, effects of memory, spiritual or mystical type experiences, aspects relating to the scanner and research environment, comparisons with other experiences, the intensity and onset of effects, and individual interpretation of the experience. DISCUSSION: This article documents the phenomenology of psilocybin when given in a novel manner (intravenous injection) and setting (an MRI scanner). The findings of the analysis are consistent with previous published work regarding the subjective effects of psilocybin. There is much scope for further research investigating the phenomena identified in this paper.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25563444     DOI: 10.2174/1874473708666150107120930

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  13 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  The acute effects of classic psychedelics on memory in humans.

Authors:  C J Healy
Journal:  Psychopharmacology (Berl)       Date:  2021-01-09       Impact factor: 4.530

Review 3.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 4.  Unifying Theories of Psychedelic Drug Effects.

Authors:  Link R Swanson
Journal:  Front Pharmacol       Date:  2018-03-02       Impact factor: 5.810

5.  Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Authors:  Eduardo Ekman Schenberg
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

Review 6.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

Review 7.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

8.  "This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Authors:  O Merve Mollaahmetoglu; Johanna Keeler; Katherine J Ashbullby; Eirini Ketzitzidou-Argyri; Meryem Grabski; Celia J A Morgan
Journal:  Front Psychiatry       Date:  2021-08-16       Impact factor: 4.157

9.  Psychedelics alter metaphysical beliefs.

Authors:  Christopher Timmermann; Hannes Kettner; Chris Letheby; Leor Roseman; Fernando E Rosas; Robin L Carhart-Harris
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

Review 10.  Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review.

Authors:  Kristin Heuschkel; Kim P C Kuypers
Journal:  Front Psychiatry       Date:  2020-03-31       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.